Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 42 |
| Active Pipeline (Recruiting Now) | 21 (10) |
| Completed vs Stopped Early | 3 / 18 (42.9%) |
| Median Closed Actual Enrollment | 24 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hospital Universitario 12 de Octubre | Madrid | 18 |
| Gustave Roussy | Villejuif, Île-de-France Region | 9 |
| Erasmus MC | Rotterdam | 9 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04031677 | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase III | RECRUITING |
| NCT06246149 | Adjuvant Tebentafusp in High Risk Ocular Melanoma | Phase III | RECRUITING |
| NCT05815927 | Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer | Phase III | RECRUITING |
| NCT05512364 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | Phase III | RECRUITING |
| NCT06809322 | Vorasidenib Maintenance for IDH Mutant Astrocytoma | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the European Organisation for Research and Treatment of Cancer - EORTC Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.